I would say that sequencing is a very big discussion. I would say that cabozantinib is already approved by the FDA and it’s part of the NCCN, ENETS and NANETS guidelines. Whether cabozantinib should be used as a second or third-line treatment in patients with functional endocrine tumors is a question that is probably answered by this trial. It can be. It can be safely used...
I would say that sequencing is a very big discussion. I would say that cabozantinib is already approved by the FDA and it’s part of the NCCN, ENETS and NANETS guidelines. Whether cabozantinib should be used as a second or third-line treatment in patients with functional endocrine tumors is a question that is probably answered by this trial. It can be. It can be safely used. When you look at the side effect profile of cabozantinib and specifically diarrhea, which is one of the main problems with patients with neuroendocrine tumors, that doesn’t seem to be much different when you compare patients with functional and non-functional tumors. So long story short, cabozantinib can be safely used, as suggested before, without determination of the functional status, without consideration of the functional status.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
